Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Antihypertensive Drugs: Potassium-Sparing Diuretics

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Identifying stakeholder behaviors for competency-based pharmacy education: A stage 1 behavior change wheel analysis.

Research in social & administrative pharmacy : RSAP·2026

Same author

A bibliometric analysis describing the global scope of pharmacist roles (2000-2024).

Journal of the American Pharmacists Association : JAPhA·2026

Same author

2025-2026 Academic Affairs Committee Report: Advancing Competency-Based Pharmacy Education and Academic Coaching.

American journal of pharmaceutical education·2026

Same author

A Bibliometric Analysis of Pharmacist-Delivered Care: Global Trends, Outcomes, and Practice Settings (2000-2024).

Journal of the American College of Clinical Pharmacy : JACCP·2026

Same author

Future-Proofing Pharmacy: A Stakeholder-Informed Forecast of Workforce and Education Needs.

Journal of the American College of Clinical Pharmacy : JACCP·2026

Same author

A unifying vision for pharmacy: Defining professional identity through stakeholder perspectives.

Journal of the American Pharmacists Association : JAPhA·2025

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Aliskiren.

Kimberly K Daugherty¹

¹Department of Clinical and Administrative Sciences, Sullivan University College of Pharmacy, Louisville, KY, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists

|July 3, 2008

Summary

This summary is machine-generated.

Aliskiren, a direct renin inhibitor, effectively lowers blood pressure in mild-to-moderate hypertension cases. It shows promise for patients unresponsive to other treatments, but caution is advised for those with renal dysfunction.

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Related Experiment Videos

Last Updated: Jul 4, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Area of Science:

Pharmacology and Therapeutics
Cardiovascular Medicine

Background:

Aliskiren represents a novel class of direct renin inhibitors, targeting the rate-limiting step of the renin-angiotensin-aldosterone system (RAAS).
Approved by the FDA in 2007, it offers a new therapeutic option for managing hypertension.

Purpose of the Study:

To review the pharmacology, pharmacokinetics, clinical efficacy, safety, and economic aspects of aliskiren.
To evaluate aliskiren's role in hypertension management, including its efficacy, adverse effects, and drug interactions.

Main Methods:

Review of existing clinical studies and pharmacological data on aliskiren.
Analysis of clinical trial data comparing aliskiren monotherapy and combination therapy with placebo and other antihypertensives.

Main Results:

Aliskiren monotherapy demonstrated a dose-dependent reduction in systolic and diastolic blood pressure (BP).
Combination therapy with hydrochlorothiazide or an angiotensin-receptor blocker yielded greater BP reductions.
Common adverse effects included headache, fatigue, dizziness, diarrhea, and nasopharyngitis.

Conclusions:

Aliskiren is a viable option for mild-to-moderate hypertension, particularly in patients with diabetes or those refractory to first-line treatments.
Further comparative studies are necessary to establish optimal patient selection for aliskiren therapy.
Caution is recommended when prescribing aliskiren to patients with moderate renal dysfunction due to its RAAS-acting mechanism.